Sylvia Boj

Sylvia Boj co-developed CRISPR-engineered organoid systems for cancer modeling and has been instrumental in translating organoid technology from academic research to commercial drug discovery platforms. She established methods for efficient CRISPR gene editing in patient-derived organoids, enabling creation of genetically defined isogenic panels that isolate the contribution of individual mutations to drug sensitivity. Her work on pancreatic cancer organoids demonstrated faithful recapitulation of disease subtypes and drug response patterns. She has built commercial organoid biobank infrastructure at HUB Organoids, making characterized tumor organoid panels accessible to pharmaceutical companies for large-scale drug screening.